DINAMIQS, a Siegfried company specializing in viral vector design and manufacturing, inaugurated its state-of-the-art cGMP manufacturing facility for viral vectors, the first of its kind in Switzerland.

The new site enables end-to-end production of viral vector gene therapies, spanning molecule design, process development, and aseptic drug product filling. It integrates research, clinical, and commercial manufacturing under one roof, providing a seamless pathway from innovation to patient-ready therapies.

The facility, located in the Bio-Technopark in Zurich, covers 2,500 m² and offers production capacity up to the 1,000L scale. Its modular, segregated design incorporates state-of-the-art closed, single-use technologies, ensuring strict containment, rapid turnaround times, and full GMP compliance. New laboratory space within the facility has been operational since the third quarter of 2024. With the opening of this site, Siegfried strengthens its position in the rapidly expanding cell and gene therapy market.

To mark the inauguration, DINAMIQS also announced a strategic collaboration with SEAL Therapeutics to advance the development and manufacturing of a novel gene therapy for LAMA2-related muscular dystrophy, a severe childhood-onset disease characterized by progressive muscle loss and currently lacking any treatment options. SEAL Therapeutics, a spin-off from the Biozentrum of the University of Basel, is led by Professor Dr. Markus Rüegg, Dr. Judith Reinhard, and Dr. Thomas Meier. Their research team will be supported by DINAMIQS experts to scale up production and move their therapy closer to clinical application.

Marcel Imwinkelried, Chief Executive Officer of Siegfried, commented: “Since acquiring DINAMIQS in 2023, our ambition has been to scale its capabilities to the commercial level and establish it as a leading CDMO in the cell and gene therapy space. With the inauguration of this new facility and the growing demand from customers, we are well on track to achieving that goal.”

He added: “One of the biggest challenges facing cell and gene therapy developers today is scalability in process development and manufacturing. With our new facility in Zurich, we provide customers with everything they need from a single partner at a single location—from lead optimization and R&D production to clinical and commercial supply. This integrated approach saves valuable time and resources, helping therapies reach patients more efficiently.”